ClinicalTrials.gg
CompletedNCT00215449Updated Nov 11, 2010

Study in Patients With COPD

A Phase 3 interventional study of Formoterol Fumarate in COPD, sponsored by Dey. Completed at 68 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-11-11.

Sponsored by Dey (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
690
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
24th of 89
690 · median 120
Phase 3
40 of 89
1 open now
Registered
4th of 89
by date
Lead sponsor
11 of 89
Dey

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 24th largest by enrollment, is one of 40 in phase 3, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.

03

Conditions studied

  • COPD

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • formoterol
  • formoterol fumarate
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical diagnosis of
  • Current or prior history of cigarette smoking

Exclusion criteria

Exclusion Criteria:

  • Medical diagnosis of asthma
  • Chest x-ray (CXR) prior to Day 1 diagnostic of significant disease other than
  • Significant condition or disease other than COPD
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
690 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Measure of lung function

Secondary outcomes

  1. Change in lung function, as well as vital signs

  2. Physical Exam results, Adverse Event reporting, etc

07

Study locations

68 sites
  • Research Site
    Bessemer, Alabama 35023, United States
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Phoenix, Arizona 85006-2666, United States
  • Research Site
    Tuscon, Arizona 85715, United States
  • Research Site
    Tuscon, Arizona 85723, United States
  • Research Site
    Tuscon, Arizona 85745, United States
  • Research Site
    Buena Park, California 90620, United States
  • Research Site
    Encinitas, California 92024, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Mission Viejo, California 92691, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    Sepulveda, California 91343, United States
  • Research Site
    Stockton, California 95207, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Wheat Ridge, Colorado 80033, United States
  • Research Site
    Hartford, Connecticut 06105, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Bay Pines, Florida 33744, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Blue Ridge, Georgia 30513, United States
  • Research Site
    Hines, Illinois 60141, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Evansville, Indiana 47714, United States
  • Research Site
    Shawnee Mission, Kansas 66216, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    Louisville, Kentucky 40215, United States
  • Research Site
    New Orleans, Louisiana 70115, United States
  • Research Site
    Slidell, Louisiana 70461, United States
  • Research Site
    Edina, Minnesota 55438, United States
  • Research Site
    Minneapolis, Minnesota 55402, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Minneapolis, Minnesota 55416, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Butte, Montana 59701, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Papillion, Nebraska 68046, United States
  • Research Site
    Henderson, Nevada 89014, United States
  • Research Site
    Cherry Hill, New Jersey 08003, United States
  • Research Site
    Springfield, New Jersey 07081, United States
  • Research Site
    Albuquerque, New Mexico 87108, United States
  • Research Site
    Larchmont, New York 10538, United States
  • Research Site
    New Hyde Park, New York 11040, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cincinnati, Ohio 45220, United States
  • Research Site
    Cincinnati, Ohio 45231, United States
  • Research Site
    Cincinnati, Ohio 45241, United States
  • Research Site
    Cincinnati, Ohio 45245, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Easton, Pennsylvania 18045, United States
  • Research Site
    Spartanburg, South Carolina 29307, United States
  • Research Site
    Austin, Texas 78750, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Houston, Texas 77024, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Richmond, Virginia 23225, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Milwaukee, Wisconsin 53209, United States
08

References and documents

Publications

  • Donohue JF, Hanania NA, Fogarty C, Campbell SC, Rinehart M, Denis-Mize K. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008 Aug;2(4):199-208. doi: 10.1177/1753465808093934. PubMed 19124372 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 11, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00215449
Lead sponsor
Dey
First posted
Sep 22, 2005
Primary completion
Dec 2005
Completion
Apr 2006
Last update
Nov 11, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion